combination therapy clinical trial intelligence

A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia

A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia is a PHASE4 clinical asset sponsored by Changhai Hospital in Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression. SEO and diligence focus: Fludarabine, Cytarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: combination therapy

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial is a PHASE2 clinical asset sponsored by Dallas VA Medical Center in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: Antioxidants, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: combination therapy

Opioid Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain

Opioid Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain is a PHASE3 clinical asset sponsored by Rutgers, The State University of New Jersey in Opioid Use. SEO and diligence focus: opioid-containing analgesic, two over-the-counter analgesics, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: combination therapy

A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients

A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients is a PHASE4 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: dapagliflozin and saxagliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: combination therapy

Holmium Laser Xpeeda Vaporesection Versus Greenlight XPS Vaporization of the Prostate for Benign Prostatic Obstruction: A Randomized Controlled Clinical Study

The clinical trial compares two advanced laser technologies for treating benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). The Holmium Xpeeda fiber is positioned as a potentially superior alternative to the Greenlight XPS system, emphasizing efficiency and reduced operative time. The successful demonstration of improved outcomes could enhance market adoption of the Xpeeda technology, particularly in the minimally invasive surgery segment. Given the prevalence of BPH, which affects a significant portion of the male population over 50, the market potential is substantial. The results may influence purchasing decisions in urology departments and impact competitive dynamics among laser device manufacturers.

Matched by modality_normalized: combination therapy

Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial

The clinical trial evaluates the combination of linagliptin and metformin against metformin alone in patients with prediabetes, a significant and growing market segment due to the rising prevalence of type 2 diabetes. The findings could position this combination therapy as a preventive strategy, potentially expanding the market for both linagliptin and metformin. Given the increasing focus on early intervention in diabetes management, successful outcomes may enhance the competitive edge of linagliptin in the diabetes treatment landscape. The trial's completion in 2019 allows for timely analysis of results, which could inform future marketing strategies and product positioning.

Matched by modality_normalized: combination therapy

Comparison of Conventional and Non-Conventional Cardiovascular Risk Factors and Their Association With Acute Coronary Syndrome

This observational study sponsored by Superior University aims to enhance the understanding of both conventional and non-conventional cardiovascular risk factors associated with ACS. The findings could lead to improved risk assessment tools and personalized interventions, potentially creating a competitive edge in the cardiovascular therapeutics market. Given the increasing focus on non-conventional risk factors, this research may position the sponsor favorably in a market that is evolving towards more holistic cardiovascular risk management strategies. The study's outcomes could attract interest from pharmaceutical companies looking to develop novel therapies or risk assessment tools targeting ACS.

Matched by modality_normalized: combination therapy

A Clinical Study Using Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers

Omeza, LLC is investigating the efficacy of its OCM™ products in combination with standard of care for treating diabetic foot ulcers, a significant market with increasing prevalence due to the rising incidence of diabetes. The trial's completion and results could position Omeza favorably in the wound care market, particularly against established products like Apligraf® and Dermagraft®. The combination therapy approach may enhance treatment outcomes, potentially leading to partnerships or acquisitions by larger pharmaceutical companies focused on diabetes-related complications. Diligence should focus on the competitive landscape, reimbursement pathways, and regulatory considerations, especially given the FDA's oversight of the investigational products.

Matched by modality_normalized: combination therapy

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

The clinical trial is focused on evaluating the efficacy and safety of CD19CAR-T therapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Given the high unmet medical need in this patient population, successful outcomes could position the sponsor, Chinese PLA General Hospital, as a key player in the CAR-T therapy market, particularly in the Asia-Pacific region. The competitive landscape includes established CAR-T therapies such as Kymriah (tisagenlecleucel) and Breyanzi (lisocabtagene maraleucel), which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on the trial's recruitment progress, potential partnerships, and regulatory pathways in China and beyond.

Matched by modality_normalized: combination therapy

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)

The INFORM2-NivEnt trial is positioned to explore the efficacy of a novel combination therapy in a pediatric population with high-risk malignancies, a segment with significant unmet medical needs. The trial's focus on specific biomarkers (high mutational load, MYC(N) amplification, high TILs, and TLS) may provide a competitive edge in precision medicine, potentially leading to a differentiated therapeutic profile. Given the limited treatment options for refractory pediatric cancers, successful outcomes could facilitate market entry and establish a strong foothold in a niche yet critical market. The collaboration with University Hospital Heidelberg and the German Cancer Research Center enhances credibility and may attract further investment or partnerships.

Matched by modality_normalized: combination therapy

Efficacy and Safety of Tislelizumab in Combination With Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL: a Multicenter, Single-arm, Prospective Clinical Study

The clinical trial investigates the efficacy and safety of Tislelizumab, a PD-1 inhibitor, in combination with chemotherapy agents (Cyclophosphamide, Mitoxantrone Liposomes) and epigenetic regulators (Chidamide, Prednisone) for treating relapsed/refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Given the aggressive nature of AITL and the limited treatment options available, successful outcomes could position Tislelizumab as a significant therapeutic option in a niche market. The trial is currently recruiting in China, indicating a potential first-mover advantage in this indication. However, the competitive landscape includes other PD-1/PD-L1 inhibitors and emerging therapies targeting similar patient populations, necessitating ongoing diligence on market dynamics and competitor developments.

Matched by modality_normalized: combination therapy

A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Disphar International B.V. is exploring the combination of Teysuno (S-1), a known oral chemotherapy agent, with epirubicin and oxaliplatin in patients with advanced solid tumors. The Phase 1 trial aims to establish the maximum tolerated dose (MTD) and assess safety and tolerability. Given the lack of established curative therapies for advanced solid tumors, this combination therapy could address a significant unmet medical need. The competitive landscape includes existing therapies for advanced solid tumors, but the unique oral formulation of S-1 may provide a differentiated offering. Diligence should focus on the safety profile and potential market acceptance of this combination therapy, especially in regions where oral chemotherapy is preferred.

Matched by modality_normalized: combination therapy

Heart Rate Variability-Guided Exercise Training in Type 2 Diabetes

The trial, sponsored by the University of Illinois at Chicago, aimed to evaluate a novel approach to exercise training for individuals with type 2 diabetes by utilizing heart rate variability (HRV) to tailor exercise prescriptions. Despite the innovative nature of this intervention, the study was withdrawn due to challenges in participant enrollment and funding cessation. The market for diabetes management solutions is substantial, with increasing demand for personalized treatment options. Companies focusing on exercise-based interventions may find competitive advantages in developing similar HRV-guided programs, especially as the prevalence of type 2 diabetes continues to rise. Diligence should consider the feasibility of recruitment strategies and funding mechanisms for future studies.

Matched by modality_normalized: combination therapy

DEVELOPMENT OF "GLYCEMIC CONTROL BAR WITH BEANS AND TOMATO FOR DIABETIC EATING" (GLYCOBITE) SNACK BAR FORMULATIONS AS A HEALTHY SNACK FOR DIABETES MELLITUS PATIENTS

The GlycoBite snack bar, developed by University Ngudi Waluyo, targets the growing market of functional foods for diabetes management. With the increasing prevalence of Type 2 Diabetes Mellitus (T2DM), the demand for healthy snack options is on the rise. This trial aims to establish the GlycoBite's effectiveness in improving glycemic control, potentially positioning it as a competitive alternative to existing commercial snack bars. The study's outcomes could influence market entry strategies and partnerships with health-focused food manufacturers. Additionally, the trial's findings may attract interest from investors and stakeholders in the health and wellness sector, particularly those focused on diabetes care.

Matched by modality_normalized: combination therapy

A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema

GX-03, developed by Turn Therapeutics, is currently in a Phase 2 clinical trial aimed at evaluating its efficacy and safety in treating moderate to severe eczema. The market for eczema treatments is substantial, with a growing demand for effective topical therapies. The trial's design includes an adaptive approach, allowing for potential enrollment expansion based on interim results, which could enhance the asset's value. Competitive analysis indicates that while several topical treatments exist, there remains a significant unmet need for effective therapies with favorable safety profiles. Successful outcomes could position GX-03 favorably against existing treatments, potentially leading to strategic partnerships or acquisition interest from larger pharmaceutical companies.

Matched by modality_normalized: combination therapy

A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control

This study compares the efficacy and safety of acarbose against voglibose in patients with type 2 diabetes inadequately controlled by insulin glargine and/or metformin. Given the increasing prevalence of type 2 diabetes globally, the potential market for effective oral hypoglycemic agents remains substantial. Bayer's positioning with acarbose could enhance its portfolio in diabetes management, particularly in markets where voglibose is a competitor. The results may influence prescribing patterns and market share dynamics, especially in regions where both drugs are available. Diligence should focus on the competitive landscape, particularly the acceptance of acarbose in clinical practice compared to voglibose and other newer agents.

Matched by modality_normalized: combination therapy

Department of Hematology, The Second Affiliated Hospital of Kunming Medical University.

This clinical trial is positioned to evaluate the efficacy and safety of Venetoclax in combination with a 3-day Decitabine regimen compared to the established Venetoclax and Azacitidine regimen in elderly or unfit patients with newly diagnosed Acute Myeloid Leukemia (AML). The target population is significant, as elderly patients represent a substantial segment of the AML market, often facing limited treatment options due to comorbidities. If successful, this trial could provide a competitive edge for Venetoclax in the AML treatment landscape, potentially expanding its market share against existing therapies. The trial's outcomes may influence treatment guidelines and reimbursement policies, thus impacting commercial strategies for stakeholders involved in AML therapeutics.

Matched by modality_normalized: combination therapy

A Single-arm, Pilot Study of Venetoclax in Combination With 5 Days Azacitidine in Treatment-naïve Subjects With Acute Myelogenous Leukemia Who Are ≥18 Years of Age and Not Eligible for Standard Induction Therapy (VENAZA-5S PILOT TRIAL)

The VENAZA-5S pilot trial is exploring a modified treatment regimen of Venetoclax in combination with a reduced duration of Azacitidine for treatment-naïve patients with Acute Myeloid Leukemia (AML) who are ineligible for standard induction therapy. This study aims to enhance tolerability and adherence, potentially leading to improved patient outcomes and quality of life. The market for AML therapies is growing, driven by the increasing incidence of the disease and the need for effective treatments for elderly and comorbid patients. AbbVie’s involvement as a collaborator indicates strategic interest in expanding the Venetoclax portfolio, which could enhance competitive positioning against other therapies in the AML space. The results of this trial may provide critical data to support further development and commercialization strategies, particularly in Europe where the standard of care is evolving.